-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On December 30, Sihuan Pharmaceutical announced that its subsidiary Yaozhong International has acquired all the shares of Genesis Biosystems in the United States
.
According to data, Genesis was established in 2001 and is a manufacturer of high-quality aesthetics and biomedical products.
It is mainly engaged in the development, manufacturing and distribution of beauty equipment, focusing on micro-channel systems and fat collection products for beauty skin care treatments and plastic surgery Surgery
.
The industry expects that this acquisition will further expand Sihuan Pharmaceutical's medical aesthetics product pipeline
.
It is understood that in recent years, Sihuan Pharmaceutical has been actively deploying the medical beauty market
.
In June 2021, Meiyen Laboratory, a US subsidiary of Sihuan Pharmaceutical, has reached a strategic cooperation with Genesis for this product, and obtained the exclusive agency rights for this product in Greater China and South Korea
.
As early as 2014, Sihuan Pharmaceutical also signed an exclusive agency agreement for botulinum toxin and hyaluronic acid products with Hugel of South Korea
.
After years of development, Sihuan Pharmaceutical has formed a product matrix of dozens of "self-research + BD" products.
It has also established the American R&D Center Meiyan Laboratory and three high-efficiency, low-cost production bases
.
The industry believes that with the smooth acquisition of the entire equity of Genesis Biosystems in the United States, the strength of Sihuan's medical and aesthetic product pipeline will be further strengthened in the future
.
On the same day, Yunnan Baiyao also issued an announcement stating that the company's second-tier wholly-owned subsidiary intends to transfer 100% of the company's third-tier wholly-owned subsidiary Yunzhen Company to the company at a net book value of 625,800 yuan for free
.
Regarding the transfer, Yunnan Baiyao stated that it is to better integrate company resources and improve decision-making efficiency
.
According to the announcement, after the completion of the transfer, the company directly holds 100% equity of Yunzhen Company and intends to increase its capital by 500 million yuan in Yunzhen Company
.
At that time, Yunzhen Company will be the setting unit of Yunnan Baiyao Skin Comprehensive Solutions Medical Center, starting with the opening of an outpatient department, promoting the ecological layout of the medical aesthetics industry chain, exploring upstream and downstream business growth models, and quickly opening up the business track.
Layout the whole ecological chain cycle of the big health industry
.
It is worth noting that Yunnan Baiyao's layout in the field of medical beauty has long been traced
.
At present, the company's medical beauty-related business is mainly based on "Caizhiji" as its brand
.
In November, the company's Caizhiji business cooperated with IBM and Omron to release an AI skin personalized customization system
.
In December, the company mentioned in an investor survey activity that the company’s Caizhiji testing sites have been deployed in 6 provinces and municipalities including Yunnan, Shanghai, Jiangsu, Guangdong, Anhui, and Guangxi, covering a total of 17 prefecture-level cities
.
Analysis believes that, in fact, the actions of the above companies are the epitome of domestic pharmaceutical companies entering the field of medical beauty
.
In recent years, under the background of the normalization of centralized procurement and the general trend of drug price reduction, many pharmaceutical companies are looking for a path of transformation due to obvious performance pressure; among them, medical beauty has clearly become a new track for many pharmaceutical companies to enter
.
At present, in addition to the above companies, data shows that as of November 15, there are 51 A-share medical aesthetics concept stocks
.
Among them, the number of listed companies from the pharmaceutical and biological industry is as high as 31, accounting for more than 60%
.
However, it should be noted that while pharmaceutical companies see the craze for medical beauty, they also need to cool down and think
.
Analysts said that medical beauty involves the health and life safety of the people.
Judging from the current tightening of national supervision, the medical beauty industry has begun a series of rectifications
.
In the future, with the continuous strengthening of policy supervision, the medical beauty industry is bound to usher in a major reshuffle
.
In this context, relevant pharmaceutical companies need to pay more attention to compliance development; and companies that want to enter the market should also think more carefully
.
.
According to data, Genesis was established in 2001 and is a manufacturer of high-quality aesthetics and biomedical products.
It is mainly engaged in the development, manufacturing and distribution of beauty equipment, focusing on micro-channel systems and fat collection products for beauty skin care treatments and plastic surgery Surgery
.
The industry expects that this acquisition will further expand Sihuan Pharmaceutical's medical aesthetics product pipeline
.
It is understood that in recent years, Sihuan Pharmaceutical has been actively deploying the medical beauty market
.
In June 2021, Meiyen Laboratory, a US subsidiary of Sihuan Pharmaceutical, has reached a strategic cooperation with Genesis for this product, and obtained the exclusive agency rights for this product in Greater China and South Korea
.
As early as 2014, Sihuan Pharmaceutical also signed an exclusive agency agreement for botulinum toxin and hyaluronic acid products with Hugel of South Korea
.
After years of development, Sihuan Pharmaceutical has formed a product matrix of dozens of "self-research + BD" products.
It has also established the American R&D Center Meiyan Laboratory and three high-efficiency, low-cost production bases
.
The industry believes that with the smooth acquisition of the entire equity of Genesis Biosystems in the United States, the strength of Sihuan's medical and aesthetic product pipeline will be further strengthened in the future
.
On the same day, Yunnan Baiyao also issued an announcement stating that the company's second-tier wholly-owned subsidiary intends to transfer 100% of the company's third-tier wholly-owned subsidiary Yunzhen Company to the company at a net book value of 625,800 yuan for free
.
Regarding the transfer, Yunnan Baiyao stated that it is to better integrate company resources and improve decision-making efficiency
.
According to the announcement, after the completion of the transfer, the company directly holds 100% equity of Yunzhen Company and intends to increase its capital by 500 million yuan in Yunzhen Company
.
At that time, Yunzhen Company will be the setting unit of Yunnan Baiyao Skin Comprehensive Solutions Medical Center, starting with the opening of an outpatient department, promoting the ecological layout of the medical aesthetics industry chain, exploring upstream and downstream business growth models, and quickly opening up the business track.
Layout the whole ecological chain cycle of the big health industry
.
It is worth noting that Yunnan Baiyao's layout in the field of medical beauty has long been traced
.
At present, the company's medical beauty-related business is mainly based on "Caizhiji" as its brand
.
In November, the company's Caizhiji business cooperated with IBM and Omron to release an AI skin personalized customization system
.
In December, the company mentioned in an investor survey activity that the company’s Caizhiji testing sites have been deployed in 6 provinces and municipalities including Yunnan, Shanghai, Jiangsu, Guangdong, Anhui, and Guangxi, covering a total of 17 prefecture-level cities
.
Analysis believes that, in fact, the actions of the above companies are the epitome of domestic pharmaceutical companies entering the field of medical beauty
.
In recent years, under the background of the normalization of centralized procurement and the general trend of drug price reduction, many pharmaceutical companies are looking for a path of transformation due to obvious performance pressure; among them, medical beauty has clearly become a new track for many pharmaceutical companies to enter
.
At present, in addition to the above companies, data shows that as of November 15, there are 51 A-share medical aesthetics concept stocks
.
Among them, the number of listed companies from the pharmaceutical and biological industry is as high as 31, accounting for more than 60%
.
However, it should be noted that while pharmaceutical companies see the craze for medical beauty, they also need to cool down and think
.
Analysts said that medical beauty involves the health and life safety of the people.
Judging from the current tightening of national supervision, the medical beauty industry has begun a series of rectifications
.
In the future, with the continuous strengthening of policy supervision, the medical beauty industry is bound to usher in a major reshuffle
.
In this context, relevant pharmaceutical companies need to pay more attention to compliance development; and companies that want to enter the market should also think more carefully
.
